Heering Jan, Jores Nathalie, Kilu Whitney, Schallmayer Espen, Peelen Evelyn, Muehler Andreas, Kohlhof Hella, Vitt Daniel, Linhard Verena, Gande Santosh L, Chaikuad Apirat, Sreeramulu Sridhar, Schwalbe Harald, Merk Daniel
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, 60596Frankfurt, Germany.
Institute for Organic Chemistry and Chemical Biology, Center for Biomolecular Magnetic Resonance (BMRZ), Goethe-University Frankfurt, 60438Frankfurt, Germany.
ACS Chem Biol. 2022 Nov 18;17(11):3159-3168. doi: 10.1021/acschembio.2c00599. Epub 2022 Nov 1.
The bile-acid sensing nuclear farnesoid X receptor (FXR) is an attractive target for the treatment of hepatic and metabolic diseases, but application of this chemotherapeutic concept remains limited due to adverse effects of FXR activation observed in clinical trials. To elucidate the mechanistic basis of FXR activation at the molecular level, we have systematically studied FXR co-regulator interactions and dimerization in response to seven chemically diverse FXR ligands. Different molecular effects on FXR activation mediated by different scaffolds were evident and aligned with characteristic structural changes within the ligand binding domain of FXR. A partial FXR agonist acted mainly through co-repressor displacement from FXR and caused an FXR-regulated gene expression pattern markedly differing from FXR agonist effects. These results suggest selective modulation of FXR dimerization and co-regulator interactions for different ligands, offering a potential avenue for the design of gene- or tissue-selective FXR modulators.
胆汁酸传感核法尼醇X受体(FXR)是治疗肝脏和代谢疾病的一个有吸引力的靶点,但由于在临床试验中观察到FXR激活的不良反应,这种化疗概念的应用仍然有限。为了在分子水平上阐明FXR激活的机制基础,我们系统地研究了FXR与共调节因子的相互作用以及在七种化学性质不同的FXR配体作用下的二聚化。不同支架介导的对FXR激活的不同分子效应是明显的,并且与FXR配体结合域内的特征性结构变化一致。一种部分FXR激动剂主要通过从FXR上置换共抑制因子起作用,并导致FXR调节的基因表达模式与FXR激动剂的效应明显不同。这些结果表明,针对不同配体对FXR二聚化和共调节因子相互作用进行选择性调节,为设计基因或组织选择性FXR调节剂提供了一条潜在途径。